4.50Open4.50Pre Close0 Volume100 Open Interest15.00Strike Price0.00Turnover142.78%IV-5.00%PremiumJan 17, 2025Expiry Date5.00Intrinsic Value100Multiplier23DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.8295Delta0.0723Gamma1.90Leverage Ratio-0.0184Theta-0.0065Rho-1.58Eff Leverage0.0064Vega
Omeros Stock Discussion
Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA
Omeros (OMER) announced successful results from its narsoplimab pivotal trial for treating transplant-associated thrombotic microangiopathy (TA-TMA). The primary statistical analysis showed that patients treated with narsoplimab had an over 3-fold reduction in mortality risk (hazard ratio = 0.32) compared to untreated p...
No comment yet